

Ho Jin Kim, MD, PhD



Biographical Sketch

Dr. Ho Jin Kim is a consultant neurologist and principal scientist at the Research Institute and Hospital of National Cancer Center, Goyang Korea. He is also professor of Department of Cancer Biomedical Science, National Cancer Center Graduate School of Cancer Science & Policy.

Dr. Kim received his medical degree from Seoul National University (1992) where he also completed his residency training in neurology (1998) and clinical fellowship in multiple sclerosis (MS) and neuromuscular disease. Dr. Kim went on to pursue his academic research interest as a research fellow in neuroimmunology at the University of Southern California, Keck School of Medicine, Los Angeles, California, USA for a year. Then he spent four years as a senior fellow and staff researcher in MS and neuroimmunology at the Montreal Neurological Institute of McGill University, Montreal, Quebec, Canada.

His major research interests lie in studying the development and application of biological assays to monitor the disease process and evaluate the response to novel therapeutics. His other research interests are in studying differences among various autoimmune inflammatory diseases of CNS including MS, neuromyelitis optica spectrum disorder and MOG-IgG associated disease in both clinical and radiological features as well as underlying pathogenesis.

Dr. Kim is widely published and a member of many prominent professional societies and associations including the American Academy of Neurology, European Neurological Society, International Society of Neuroimmunology, The Federation of Clinical Immunology Societies, the Korean Neurological Association, and the Korean Society of Multiple Sclerosis. He is a vice-president of Pan-Asian Committee of Treatment and Research for Multiple Sclerosis (PACTRIMS) and a member of executive and organizing committee of PACTRIMS. He also serves as a co-editor for Multiple Sclerosis Journal and an associated editor for Journal of Clinical Neurology.

Publications

1. Jarius S, Paul F, Weinshenker BG, Levy M, [Kim HJ](#), Wildemann B. Neuromyelitis optica. *Nat Rev Dis Primers*. 2020 Oct 22;6(1):85.
2. Specovius S, Zimmermann HG, Oertel FC, Chien C, Bereuter C, Cook LJ, Lana Peixoto MA, Fontenelle MA, [Kim HJ](#), Hyun JW, Jung SK, Palace J, Roca-Fernandez A, Diaz AR, Leite MI, Sharma SM, Ashtari F, Kafieh R, Dehghani A, Pourazizi M, Pandit L, Dcunha A, Aktas O, Ringelstein M, Albrecht P, May E, Tongco C, Leocani L, Pisa M, Radaelli M, Martinez-Lapiscina EH, Stiebel-Kalish H, Hellmann M, Lotan I, Siritho S, de Seze J, Senger T, Havla J, Marignier R, Tilikete C, Cobo Calvo A, Bichuetti DB, Tavares IM, Asgari N, Soelberg K, Altintas A, Yildirim R, Tanriverdi U, Jacob A, Huda S, Rimler Z, Reid A, Mao-Draayer Y, de Castillo IS, Yeaman MR, Smith TJ, Brandt AU, Paul F; GJCF International Clinical Consortium for NMOSD. Cohort profile: a collaborative multicentre study of retinal optical coherence tomography in 539 patients with neuromyelitis optica spectrum disorders (CROCTINO). *BMJ Open*. 2020 Oct 29;10(10):e035397.
3. MY Lee, KP Kok, JW Hyun, SH Kim, SY Lee, [HJ Kim](#). Incidence of inter-attack asymptomatic brain lesions in NMO spectrum disorder. *Neurology*. 2020 Sep 14;10.1212/WNL.0000000000010847.
4. Hyun JW, Lee HL, Jeong WK, Lee HJ, Shin JH, Min JH, Kim BJ, Kim SW, Shin HY, Oh J, Kim W, Shin HJ, Oh SY, Kim H, Lim YM, Huh SY, Cho EB, Nam TS, Lee SH, Kim SY, Kang SY, Han SG, Sohn EH, Baek SH, Kim BJ, Lee SS, Seok JM, Hong YH, Oh SJ, Kim JK, Shin KJ, Kwon O, Cho JY, Bae JS, Kim SY, Kim Y, Lee MY, Kim SH, [Kim HJ](#). Comparison of MOG and AQP4 antibody seroprevalence in Korean adults with inflammatory demyelinating CNS diseases. *Mult Scler*. 2020 Aug 11. [Epub ahead of print]
5. Yoo IH, Kim W, Shim Y, Choi SA, Kim SY, Kim H, Lim BC, Hwang H, Choi J, Kim KJ, Kim Y, Hyun JW, Kim SH, Choi K, [Kim HJ](#), Chae JH. Clinical Spectrum of Myelin Oligodendrocyte Glycoprotein-Immunoglobulin G-Associated Disease in Korean Children. *J Clin Neurol*. 2020;16:461-469.
6. Kim W, [Kim HJ](#). Monoclonal Antibody Therapies for Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder. *J Clin Neurol*. 2020;16:355-368.
7. Whittam DH, Cobo-Calvo A, Lopez-Chiriboga AS, Pardo S, Gornall M, Cicconi S, Brandt A, Berek K, Berger T, Jelcic I, Gombolay G, Oliveira LM, Callegaro D, Kaneko K, Misu T, Capobianco M, Gibbons E, Karthikeyan V, Brochet B, Audoin B, Mathey G, Laplaud D, Thouvenot E, Cohen M, Tourbah A, Maillart E, Ciron J, Deschamps R, Biotti D, Rostasy K, Neuteboom R, Hemingway C, Forsyth R, Matiello M, Webb S, Hunt D, Murray K, Hacohen Y, Lim M, Leite MI, Palace J, Solomon T, Lutterotti A, Fujihara K, Nakashima I, Bennett JL, Pandit L, Chitnis T, Weinshenker BG, Wildemann B, Sato DK, Kim SH, Huda S, [Kim HJ](#), Reindl M, Levy M, Jarius S, Tenenbaum S, Paul F, Pittock S, Marignier R, Jacob A. Treatment of MOG antibody associated disorders: results of an international study of 121 patients. *Mult Scler Relat Disord*. 2020 Jun 2;44:102251.

8. KP Kok, [HJ Kim](#). Disease modifying therapies and infection risks in multiple sclerosis—a decision-making conundrum. *Ann Transl Med*. 2020 Jun; 8(11): 722.
9. JW Hyun, YN Kwon, SM Kim, HL Lee, WK Jeong, HJ Lee, BJ Kim, SW Kim, HY Shin, HJ Shin, SY Oh, SY Huh, W Kim, MS Park, J Oh, H Jang, NY Park, MY Lee, SH Kim, [HJ Kim](#). Value of Area Postrema Syndrome in Differentiating Adults with AQP4 vs. MOG Antibodies. *Front Neurol*. 2020; 11: 396. Published online 2020 Jun 4
10. Iacobaeus E, Arrambide G, Pia Amato M, Derfuss T, Vukusic S, Hemmer B, Tintore M, Brundin L; 2018ECTRIMS Focused Workshop Group. Aggressive multiple sclerosis (1): Towards a definition of the phenotype. *Mult Scler*. 2020 Jun 12. [Epub ahead of print]
11. Arrambide G, Iacobaeus E, Amato MP, Derfuss T, Vukusic S, Hemmer B, Brundin L, Tintore M; 2018ECTRIMS Focused Workshop Group. Aggressive multiple sclerosis (2): Treatment. *Mult Scler*. 2020 Jun 12. [Epub ahead of print]
12. Kim SH, Choi MK, Park NY, Hyun JW, Lee MY, [Kim HJ](#), Jung SK, Cha Y. Serum neurofilament light chain levels as a biomarker of neuroaxonal injury and severity of oxaliplatin-induced peripheral neuropathy. *Sci Rep*. 2020 May 14;10(1):7995.
13. Kim SH, Huh SY, Jang H, Park NY, Kim Y, Jung JY, Lee MY, Hyun JW, [Kim HJ](#). Outcome of pregnancies after onset of the neuromyelitis optica spectrum disorder. *Eur J Neurol*. 2020 Apr 22. [Epub ahead of print]
14. Kim W, Park EY, Hyun JW, Huh SY, Park NY, Jang H, Kim SH, [Kim HJ](#). Validation of the Korean Version of the 12-Item Multiple Sclerosis Walking Scale and Application to Neuromyelitis Optica Spectrum Disorder. *J Clin Neurol*. 2020 Apr;16(2):270-276.
15. Hyun JW, Kwon YN, Lee HL, Jeong WK, Lee HJ, Kim BJ, Kim SW, Shin HY, Shin HJ, Oh SY, Lee MY, Kim SH, Huh SY, Kim W, Park MS, Kim SY, Kim SM, [Kim HJ](#). Recurrence of clinical events at the same anatomical location in patients with MOG antibody-associated disease. *Mult Scler*. 2020 Mar 31 [Epub ahead of print]
16. Yong KP, [Kim HJ](#). Smelling the danger. *Mult Scler*. 2020 Mar 31 [Epub ahead of print]
17. Lee J, Hyun JW, Lee J, Choi EJ, Shin HG, Min K, Nam Y, [Kim HJ](#), Oh SH. So You Want to Image Myelin Using MRI: An Overview and Practical Guide for Myelin Water Imaging. *J Magn Reson Imaging*. [Epub 2020 Feb 3]
18. Kim Y, Hyun JW, Woodhall MR, Oh YM, Lee JE, Jung JY, Kim SY, Lee MY, Kim SH, Kim W, Irani SR, Waters P, Choi K, [Kim HJ](#). Refining cell-based assay to detect MOG-IgG in patients with central nervous system inflammatory diseases. *Mult Scler Relat Disord*. 2020 Jan 9;40:101939.
19. Hyun JW, Jang H, Yu J, Park NY, Kim SH, Huh SY, Kim W, Park MS, Oh J, Park KD, [Kim HJ](#). Comparison of Neuropathic Pain in Neuromyelitis Optica Spectrum Disorder and Multiple Sclerosis. *J Clin Neurol*. 2020;16:124-130.
20. Comi G, Alroughani R, Boster AL, Bass AD, Berkovich R, Fernández Ó, [Kim HJ](#), Limmroth V, Lycke J, Macdonell RA, Sharrack B, Singer BA, Vermersch P, Wiendl H, Ziemssen T, Jacobs A, Daizadeh N, Rodriguez CE, Trabouisee A; CARE-MS I, CARE-MS II, CAMMS03409, and TOPAZ Investigators. Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studies. *Mult Scler*. 2019 Nov 25 [Epub ahead of print]
21. Kim JE, Park SH, Han K, [Kim HJ](#), Shin DW, Kim SM. Prevalence and incidence of neuromyelitis optica spectrum disorder and multiple sclerosis in Korea. *Mult Scler*. 2019 Nov 21 [Epub ahead of print]
22. Wiendl H, Carraro M, Comi G, Izquierdo G, [Kim HJ](#), Sharrack B, Tornatore C, Daizadeh N, Chung L, Jacobs AK, Hogan RJ, Wychowski LV, Van Wijmeersch B; CARE-MS I, CARE-MS II, and CAMMS03409 Investigators. Lymphocyte pharmacodynamics are not associated with autoimmunity or efficacy after alemtuzumab. *Neurol Neuroimmunol Neuroinflamm*. 2019 Oct 29;7(1). pii: e635
23. Hyun JW, Kim GS, Kim SH, Cho JY, Kim HJ, Lee GK, [Kim HJ](#), Kwon SU. Fatal Simultaneous Multi-organ Failure Following Pembrolizumab Treatment for Refractory Thymoma. *Clin Lung Cancer*. 2019 Oct 19. pii: S1525-7304(19)30282-7 [Epub 2019 Oct 19]
24. Kim NH, [Kim HJ](#), Park CY, Jeong KS. Retinal Degeneration After First-Ever Optic Neuritis Helps Differentiate Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder. *Front Neurol*. 2019 Oct 10;10:1076.
25. Kim SH, Kim Y, Jung JY, Park NY, Jang H, Hyun JW, [Kim HJ](#). High Seroprevalence and Index of Anti-John-Cunningham Virus Antibodies in Korean Patients with Multiple Sclerosis. *J Clin Neurol*. 2019 Oct;15:454-460.
26. Cree BAC, Bennett JL, Kim HJ, Weinschenker BG, Pittock SJ, Wingerchuk DM, Fujihara K, Paul F, Cutter GR, Marignier R, Green AJ, Aktas O, Hartung HP, Lublin FD, Drappa J, Barron G, Madani S, Ratchford JN, She D, Cimbora D, Katz E; N-MOMentum study investigators. A randomised, placebo-controlled, double-blind trial of inebilizumab for the treatment of neuromyelitis optica spectrum disorder: results of the N-MOMentum study. *Lancet*. 2019;394:1352-1363. [Epub 2019 Sep 5]
27. Shin HJ, Hyun JW, Kim SH, Park MS, Sohn EH, Baek SH, Kim BJ, Choi K, Oh J, Cho JY, Kwon O, Kim W, Kim JE, Min JH, Kim BJ, Oh SY, Bae JS, Park KH, Oh JH, Sohn SY, Jang MJ, Sung JJ, [Kim HJ](#), Kim SM. Changing patterns of multiple sclerosis in Korea: Toward a more baseline MRI lesions and intrathecal humoral immune responses. *Mult Scler Relat Disord*. 2019;35:209-214. [Epub 2019 Aug 5].
28. Hyun JW, Shin HJ, Jang H, Park NY, Kum SH, [Kim HJ](#). Therapeutic Outcome of Alemtuzumab in Korean Patients with Multiple Sclerosis: 2-Year Follow-Up. *J Clin Neurol*. 2019;15:1-6
29. Pittock SJ, Berthele A, Fujihara K, [Kim HJ](#), Levy M, Palace J, Nakashima I, Terzi M, Totolyan N, Viswanathan S, Wang KC, Pace A, Fijita KP, Armstrong R, Wingerchuk DM. Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder. *N Engl J Med*. 2019;381:614-625 [Epub 2019 May 3]
30. Hyun JW, Kim S, Shin HS, Yun JY, Kim SY, Kim SH, Kim JK, Jeong JH, Yoo H, Gwak HS, [Kim HJ](#). Cerebrospinal Fluid CYFRA 21-1 as a Diagnostic Indicator for Leptomeningeal Metastasis in Cancer Patients. *J Korean Neurol Assoc* 2019;37:161-165, 2019
31. Hyun JW, Kim Y, Kim G, Kim SH, [Kim HJ](#). Longitudinal analysis of serum neurofilament light chain: A potential therapeutic monitoring biomarker for multiple sclerosis. *Mult Scler*. 2019 Mar 26 [Epub ahead of print]
32. Park SJ, Kim JK, Kim HH, Yoon BA, Ji DY, Lee CW, [Kim HJ](#), Kim KH, Shin HY, Park SJ, Lee DY. Integrative metabolomics reveals unique metabolic traits in Guillain-Barré Syndrome and its variants. *Sci Rep*. 2019 Jan 31;9(1):1077
33. Mealy MA, Mossburg SE, Kim SH, Messina S, Leite MI, Paul F, Palace J, [Kim HJ](#), Levy M. Long-term disability in neuromyelitis optica spectrum disorder with a history of myelitis is associated with age at onset, delay in diagnosis/preventive treatment, MRI lesion length and presence of symptomatic brain lesions. *Multiple Sclerosis and Related Disorders*. 2019;28:64-68
34. Kim SH, Hyun JW, [Kim HJ](#). Individualized B cell-targeting therapy for neuromyelitis optica spectrum disorder. *Neurochem Int*. 2018 Dec 1. [Epub ahead of print]
35. Whittam DH, Tallantyre EC, Jolles S, Huda S, Moots RJ, [Kim HJ](#), Robertson NP, Cree BAC, Jacob A. Rituximab in neurological disease: principles, evidence and practice. *Pract Neurol*. 2019;19:5-20. [Epub 2018 Nov 29]
36. Hyun JW, Kim Y, Kim G, Kim SH, [Kim HJ](#). Severe B cell-mediated disease activation despite two cycles of alemtuzumab in a patient with multiple sclerosis. *Mult Scler*. 2018 Nov 7. [Epub ahead of print]
37. Kim Y, Kim G, Shin HJ, Hyun JW, Kim SH, Lee E, [Kim HJ](#). Restoration of regulatory B cell deficiency following alemtuzumab therapy in patients with relapsing multiple sclerosis. *J Neuroinflammation*. 2018 Oct 30;15(1):300.
38. Kim SH, Mealy MA, Levy M, Schmidt F, Ruprecht K, Paul F, Ringelstein M, Aktas O, Hartung HP, Asgari N, Tsz-Ching JL, Siritho S, Prayoonwivat N, Shin HJ, Hyun JW, Han M, Leite MI, Palace J, [Kim HJ](#). Racial differences in neuromyelitis optica spectrum disorder. *Neurology*. 2018;91:e2089-e2099. [Epub 2018 Oct 26]
39. Kim SH, Park MS, Kim W, Huh SY, Shin HJ, Hyun JW, [Kim HJ](#). Real-world effectiveness of disease-modifying therapies in Korean patients with relapsing multiple sclerosis. *J Clin Neurol*. 2018 Oct 26. [Epub ahead of print]
40. Choi JY, Jeong IH, Oh SH, Oh CH, Park NY, [Kim HJ](#), Lee J. Evaluation of Normal-Appearing White Matter in Multiple Sclerosis Using Direct Visualization of Short Transverse Relaxation Time Component (ViSta) Myelin Water Imaging and Gradient Echo and Spin Echo (GRASE) Myelin Water Imaging. *J Magn Reson Imaging*. 2018 Sep 21. doi: 10.1002/jmri.26278. [Epub ahead of print]
41. Hyun JW, Kim W, Huh SY, Park MS, Ahn SW, Cho JY, Kim BJ, Lee SH, Kim SH, [Kim HJ](#). Application of the 2017 McDonald diagnostic criteria for multiple sclerosis in Korean patients with clinically isolated syndrome. *Mult Scler*. 2018 Jul 25 [Epub ahead of print]

42. Kim SH, Kim Y, Kim G, Park NY, Jang HM, Shin HJ, Hyun JW, [Kim HJ](#). Less frequent rituximab retreatment maintains remission of neuromyelitis optica spectrum disorder, following long-term rituximab treatment. *J Neurol Neurosurg Psychiatry*. 2019;90:486-487 [Epub 2018 Jun 21]
43. Jarius S, Paul F, Aktas O, Asgari N, Dale RC, de Seze J, Franciotta D, Fujihara K, Jacob A, [Kim HJ](#), Kleiter I, Kumpfel T, Levy M, Palace J, Ruprecht K, Saiz A, Trebst C, Weinschenker BG, Wildemann B. MOG encephalomyelitis: International recommendations on diagnosis and antibody testing. *J Neuroinflammation*. 2018;15(1):134.
44. Hyun JW, Huh SY, Shin HJ, Woodhall M, Kim SH, Irani SR, Lee SH, Waters P, [Kim HJ](#). Evaluation of brain lesion distribution criteria at disease onset in differentiating MS from NMOSD and MOG-IgG-associated encephalomyelitis. *Mult Scler*. 2019 ;25:585-590 [Epub 2018 Mar 1]
45. Hyun JW, Kim G, Kim Y, Kong B, Joung A, Park NY, Jang H, Shin HJ, Kim SH, Ahn SW, Shin HY, Huh SY, Kim W, Park MS, Kim BJ, Kim BJ, Oh J, [Kim HJ](#). Neutralizing Antibodies against Interferon-beta in Korean Patients with Multiple Sclerosis. *J Clin Neurol*. 2018;14:186-190. [Epub 2018 Feb 28]
46. Kim NH, [Kim HJ](#), Park CY, Jeong KS, Cho JY. Optical Coherence Tomography versus Visual Evoked Potentials for Detecting Visual Pathway Abnormalities in Patients with Neuromyelitis Optica Spectrum Disorder. *J Clin Neurol*. 2018;14:200-205. [Epub 2018 Feb 28]
47. Kim SH, Kim W, Kim JH, Woo MK, Baek JY, Kim SY, Chung SH, [Kim HJ](#). A prospective study on chronic oxaliplatin-induced neuropathy in patients with colon cancer: long-term outcomes and predictors of severe oxaliplatin-induced neuropathy. *J Clin Neurol*. 2018 Jan; 14(1): 81-89.
48. Kong BS, Kim Y, Kim GY, Hyun JW, Kim SH, Jeong A, [Kim HJ](#). Increased frequency of IL-6-producing non-classical monocytes in neuromyelitis optica spectrum disorder. *J Neuroinflammation*. 2017;14:191.
49. Kim SH, Park EY, Park B, Hyun JW, Park NY, Joung A, Lee SH, [Kim HJ](#). Multimodal magnetic resonance imaging in relation to cognitive impairment in neuromyelitis optica spectrum disorder. *Sci Rep*. 2017;7:9180.
50. [Kim HJ](#), Evoli A. Immune checkpoints inhibitor therapy: A double-edged sword? *Neurology* 2017;89:1-2 [Epub 2017 Aug 18]
51. Mealy MA, Kim SH, Schmidt F, López R, Jimenez Arango JA, Paul F, Wingerchuk DM, Greenberg BM, [Kim HJ](#), Levy M. Aquaporin-4 serostatus does not predict response to immunotherapy in neuromyelitis optica spectrum disorders. *Mult Scler*. [Epub 2017 Aug 1]
52. Kim HH, Jeong IH, Hyun JS, Kong BS, [Kim HJ](#), Park SJ. Metabolomic profiling of CSF in multiple sclerosis and neuromyelitis optica spectrum disorder by nuclear magnetic resonance. *PLoS One*. 2017;12:e0181758.
53. Hyun JW, Woodhall MR, Kim SH, Jeong IH, Kong BS, Kim G, Kim Y, Park MS, Irani SR, Waters P, [Kim HJ](#). Longitudinal analysis of myelin oligodendrocyte glycoprotein antibodies in CNS inflammatory diseases. *J Neurol Neurosurg Psychiatry*. 2017;88:811-817. [Epub 2017 Jul 06]
54. Kim SH, Hyun JW, [Kim HJ](#), Gwak HS, Lee SH, Hong EK, Lee Y. De novo cystic brain lesions mimicking neurocysticercosis in ALK-positive lung cancer. *Lung Cancer*. 2017;110:53-55. [Epub 2017 Jun 12]
55. Kim SH, [Kim HJ](#). A step forward towards personalised immunosuppressive therapy in neuromyelitis optica spectrum disorder. *J Neurol Neurosurg Psychiatry*. 2017;88:619. [Epub 2017 Jun 12]
56. Hyun JW, Park JH, Kang BG, Lee HW, Jeong JH, Joo J, Park EY, Park B, Kim JK, Kim SH, Cho KG, Park KD, Hwang SH, Gwak HS, [Kim HJ](#). Diagnostic and Prognostic Values of Cerebrospinal Fluid CYFRA 21-1 in Patients with Leptomeningeal Carcinomatosis. *Oncotarget*. 2017;8:533326-53335. [Epub 2017 Jun 8]
57. Kim SH, Kwak K, Hyun JW, Joung A, Lee SH, Choi YH, Lee JM, [Kim HJ](#). Diffusion tensor imaging of normal-appearing white matter in patients neuromyelitis optica spectrum disorder and multiple sclerosis. *Eur J Neurol*. 2017;24:966-974. [Epub 2017 May 18]
58. Hyun JW, Huh SY, Kim W, Park MS, Ahn SW, Cho JY, Kim BJ, Lee SH, Kim SH, [Kim HJ](#). Evaluation of 2016 MAGNIMS MRI criteria for dissemination in space in patients with a clinically isolated syndrome. *Mult Scler*. 2018;24:758-766. [Epub 2017 May 1]
59. Asgari N, Flanagan EP, Fujihara K, [Kim HJ](#), Skejoe HP, Wuerfel J, Kuroda H, Kim SH, Maillart E, Marignier R, Pittock SJ, Paul F, Weinschenker BG. Disruption of the leptomeningeal blood barrier in neuromyelitis optica spectrum disorder. *Neurol Neuroimmunol Neuroinflamm*. 2017 Jul; 4: e343. [Epub 2017 Apr 21]
60. Kim Y, Kim G, Kong BS, Lee JE, Oh YM, Hyun JW, Kim SH, Joung A, Kim BJ, Choi K, [Kim HJ](#). Large-scale in-house cell-based assay for evaluating the serostatus in patients with neuromyelitis optica spectrum disorder based on new diagnostic criteria. *J Clin Neurol*. 2017;13:175-180. [Epub 2017 Mar 6]
61. Jeong IH, Choi JY, Kim SH, Hyun JW, Joung A, Lee J, [Kim HJ](#). Normal appearing white matter demyelination in neuromyelitis optica spectrum disorder. *Eur J Neurol*. 2017;24:652-658 [Epub 2017 Feb 24]
62. Kim SH, [Kim HJ](#). Rituximab in neuromyelitis optica spectrum disorders: why not as first-line therapy. *JAMA Neurol*. 2017;74:482. [Epub 2017 Feb 2]
63. Ahn YH, Jeon SB, Chang CY, Goh EA, Kim SS, [Kim HJ](#), Song J, Park EJ. Glatiramer acetate attenuates the activation of CD4+ T cells by modulating STAT1 and -3 signaling in glia. *Scientific Reports*. 2017 Jan 17;7:40484.
64. Kim SH, Hyun JW, [Kim HJ](#). Rituximab for the treatment of neuromyelitis optica spectrum disorder. *J Mult Scler*. 2017;8:1-8
65. Kim SH, Hyun JW, Joung AR, Park EU, Joo J, [Kim HJ](#). Predictors of response to first-line immunosuppressive therapy in neuromyelitis optica spectrum disorders. *Mult Scler*. [Epub 2017 Jan 12]
66. Huh SY, Kim SH, Hyun JW, Jeong IH, Park MS, Lee SH, [Kim HJ](#). Short segment myelitis as a first manifestation of neuromyelitis optica spectrum disorders. *Mult Scler*. [Epub 2017 Jan 9]
67. Hyun JW, Park G, Kwak K, Jo, HJ, Joung AR, Kim JH, Lee SY, Kim S, Lee JM, Kim SH, [Kim HJ](#). Deep grey matter atrophy in neuromyelitis optica spectrum disorder and multiple sclerosis. *Eur J Neurol*. 2017;24:437-445 [Epub 2016 Dec 23]
68. Kim SH, Hyun JW, Joung AR, Lee SH, [Kim HJ](#). Occurrence of asymptomatic acute neuromyelitis optica spectrum disorder-typical brain lesions during an attack of optic neuritis or myelitis. *PLoS One*. 2016 Dec 9;11(12):e0167783.
69. Park SJ, Jeong IH, Kong BS, Lee EJ, Kim KH, Lee DY, [Kim HJ](#). Disease type- and status-specific alteration of CSF metabolome coordinated with clinical parameters in inflammatory demyelinating diseases of CNS. *PLoS One*. 2016 Nov 17;11(11):e0166277.
70. Hyun JW, Kim G, Kim Y, Jeong IH, Kim SH, [Kim HJ](#). Severe relapse after cessation of immunosuppressive therapy in a patient with neuromyelitis optica spectrum disorder. *Neurologist*. 2016;21:97-98.
71. Lee J, McKinney KQ, Pavlopoulos AJ, Han MH, Kim SH, [Kim HJ](#), Hwang S. Exosomal proteome analysis of cerebrospinal fluid detects biosignatures of neuromyelitis optica and multiple sclerosis. *Clin Chim Acta*. 2016;462:118-126. [Epub 2016 Sep 6]
72. [Kim HJ](#), Lee J. Response to letter regarding article 'Comparison of myelin water fraction values in periventricular white matter lesions between multiple sclerosis and neuromyelitis optica spectrum disorder. *Mult Scler*. 2016 Aug 5. pii: 1352458516662730. [Epub 2016 Aug 5]
73. Hyun JW, Jeong IH, Joung AR, Kim SH, [Kim HJ](#). Evaluation of the 2015 diagnostic criteria for neuromyelitis optica spectrum disorder. *Neurology*. 2016;86:1772-1779. [Epub 2016 Apr 13]
74. Jeong IH, [Kim HJ](#), Kim NH, Jeong KS, Park CY. Subclinical primary retinal pathology in neuromyelitis optica spectrum disorder. *J Neurol*. 2016;263:1343-1348. [Epub 2016 May 3]
75. Kim SH, [Kim HJ](#). Central nervous system neuroinflammatory disorders in Asian/Pacific regions. *Curr Opin Neurol*. 2016;29:372-380.
76. Kim SH, Kwak K, Hyun JW, Jeong IH, Jo HJ, Joung A, Kim JH, Lee SH, Yun S, Joo J, Lee JM, , [Kim HJ](#). Widespread cortical thinning in patients with neuromyelitis optica spectrum disorder. *Eur J Neurol*. 2016;23:1165-1173. [Epub 2016 Apr 24]
77. Park J, Kim HJ, Hyun JW, [Kim HJ](#), Kim TK, Jung A, Lee HW, Park JH, Choi KG, Lee YJ, Yun JY. Acute disseminated encephalomyelitis with tremor as the initial symptom. *Neurol Asia*. 2016;21:89-91
78. Hyun JW, Kong BS, Joung AR, Jeong IH, Kim SH, [Kim HJ](#). Neutralizing antibodies in Korean multiple sclerosis patients treated with Interferon-beta: Preliminary study. *J Mult Scler* 2016;7:9-13
79. Kim SH, Kwak K, Jeong IH, Hyun JW, Jo HJ, Joung A, Yu ES, Kim JH, Lee SH, Yun S, Joo J, Lee DK, Lee JM, [Kim HJ](#). Cognitive impairment differs between neuromyelitis optica spectrum disorder and multiple sclerosis. *Mult Scler*. [Epub 2016 Feb 26]
80. Jeong IH, Choi JY, Kim SH, Hyun JW, Joung A, Lee J, [Kim HJ](#). Comparison of myelin water fraction values in periventricular white matter lesions between multiple sclerosis and neuromyelitis optica spectrum disorder. *Mult Scler*. [Epub 2016 Feb 26]

81. Hyun JW, Kim SH, Jeong IH, Kim HT, [Kim HJ](#). Successful treatment of Lambert-Eaton myasthenic syndrome in a small cell lung cancer patient using 3,4-diaminopyridine: A case report. *Oncol Lett.* 2016;11:1933-1935. [Epub 2016 Jan 18].
82. Hyun JW, Jeong IH, Joung AR, Cho HJ, Kim SH, [Kim HJ](#). Leptomeningeal metastasis: Clinical experience of 519 cases. *Eur J Cancer.* 2016;56:107-114. [Epub 2016 Feb 1].
83. Kim W, Lee JE, Kim SH, Huh SY, Hyun JW, Jeong IH, Park MS, Cho JY, Lee SH, Lee KS, [Kim HJ](#). Cerebral cortex involvement in neuromyelitis optica spectrum disorder. *J Clin Neurol.* 2016;12:188-193. [Epub 2016 Jan 28].
84. Kaneko K, Sato DK, Nakashima I, Nishiyama S, Tanaka S, Marignier R, Hyun JW, Oliveira LM, Reindl M, Seifert-Held T, Sepulveda M, Siritho S, Waters PJ, Kurosawa K, Akaishi T, Kuroda H, Misu T, Prayoonwiwat N, Berger T, Saiz A, Kim HJ, Nomura K, Callegaro D, Fujihara K, Aoki M. Myelin Injury without astrocytopathy in neuroinflammatory disorders with MOG antibody. *J Neurol Neurosurg Psychiatry.* [Epub 2016 Jan 22].
85. Cree BA, Bennett JL, Sheehan M, Cohen J, Hartung HP, Aktas O, Kim HJ, Paul F, Pittock S, Weinschenker B, Wingerchuk D, Fujihara K, Cutter G, Patra K, Flor A, Barron G, Madani S, Ratchford JN, Katz E. Placebo-controlled study in neuromyelitis optica-Ethical and design considerations. *Mult Scler.* 2016;22:862-72. [Epub 2015 Dec 14].
86. Hyun JW, Kim SH, Jeong IH, Joung AR, Kim JH, Cho HJ, [Kim HJ](#). Increased frequency and severity of restless legs syndrome in patients with neuromyelitis optica spectrum disorder. *Sleep Med* 2016;17:121-123. [Epub 2015 Oct 22].
87. Juryńczyk M, Weinschenker B, Akman-Demir G, Asgari N, Barnes D, Boggild M, Chaudhuri A, D'hooghe M, Evangelou N, Gerales R, Illes Z, Jacob A, [Kim HJ](#), Kleiter I, Levy M, Marignier R, McGuigan C, Murray K, Nakashima I, Pandit L, Paul F, Pittock S, Selmaj K, de Sèze J, Siva A, Tanasescu R, Vukusic S, Wingerchuk D, Wren D, Leite I, Palace J. Status of diagnostic approaches to AQP4-IgG seronegative NMO and NMO/MS overlap syndromes. *J Neurol.* 2016;263:140-149. [Epub 2015 Nov 3].
88. Jeong IH, Kim SH, Hyun JW, Joung AR, Jo HJ, [Kim HJ](#). Tumefactive demyelinating lesions as a first clinical event: Clinical, imaging, and follow-up observations. *J Neurol Sci.* 2015;358:118-24. [Epub 2015 Aug 21].
89. Melamed E, Levy M, Waters PJ, Sato DK, Bennett JL, John GR, Hooper DC, Saiz A, Bar-Or A, [Kim HJ](#), Pandit L, Leite MI, Asgari N, Kissani N, Hintzen R, Marignier R, Jarius S, Marcelletti J, Smith TJ, Yeaman MR, Han MH, Aktas O, Apiwattanakul M, Banwell B, Bichuetti D, Broadley S, Cabre P, Chitnis T, De Seze J, Fujihara K, Greenberg B, Hellwig K, Iorio R, Jarius S, Klawiter E, Kleiter I, Lana-Peixoto M, Nakashima, O'Connor K, Palace J, Paul F, Prayoonwiwat N, Ruprecht K, Stuve O, Tedder T, Tenembaum S, Garrahan JP, Aires B, van Herle K, van Pelt D, Villoslada P, Waubant E, Weinschenker B, Wingerchuk D, Würfel J, Zamvil S. Update on biomarkers in neuromyelitis optica. *Neurol Neuroimmunol Neuroinflamm.* 2015 Jul 23;2(4):e134.
90. Kim SH, Jeong IH, Hyun JW, Joung AR, Jo HJ, Hwang SH, Yun S, Joo J, [Kim HJ](#). Treatment outcomes with rituximab in 100 patients with neuromyelitis optica: influence of FCGR3A polymorphism on the therapeutic response to rituximab. *JAMA Neurol.* 2015;71:989-998. [Epub 2015 Jul 13].
91. Hyun JW, Kim JY, Choi KG, [Kim HJ](#), Park KD. The Etiological Spectrum of Acute Sensory Myelitis. *J Clin Neurol.* 2015;11:227-233
92. Jeong IH, Park B, Kim SH, Hyun JW, Joo J, [Kim HJ](#). Comparative analysis of treatment outcomes in patients with neuromyelitis optica spectrum disorder using multifaceted endpoints. *Mult Scler.* 2015 Jun 4. [Epub ahead of print].
93. Hyun JW, Kim SH, Jeong IH, Ahn SW, Huh SY, Park MS, Eom YI, Joo IS, Cho JY, Cho EB, Min JH, Kim BJ, Kim NH, Oh J, Park KD, [Kim HJ](#). Utility of the Rio score and modified Rio score in Korean patients with multiple sclerosis. *PLoS One.* 2015 May 26;10(5):e0129243.
94. Kremer S, Renard F, Achard S, Lana-Peixoto MA, Palace J, Asgari N, Klawiter EC, Tenembaum SN, Banwell B, Greenberg BM, Bennett JL, Levy M, Villoslada P, Saiz A, Fujihara K, Chan KH, Schippling S, Paul F, [Kim HJ](#), de Seze J, Wuerfel JT; and the Guthy-Jackson Charitable Foundation NMO International Clinical Consortium and Biorepository. Use of Advanced Magnetic Resonance Imaging Techniques in Neuromyelitis Optica Spectrum Disorder. *JAMA Neurol.* 2015;72:815-822. [Epub 2015 May 26].
95. Hyun JW, Kim SH, Jeong IH, Lee SH, Eom HS, [Kim HJ](#). Teaching NeuroImages: Periventricular restricted diffusion MRI in CMV ventriculitis. *Neurology.* 2015 Apr 21;84:e121
96. Hyun JW, Joung AR, Jeong IH, Kim SH, [Kim HJ](#). Healthcare costs of multiple sclerosis in Korea according to the level of disability. *J Mult Scler.* 2015;6:9-13.
97. Huh SY, Kim SH, [Kim HJ](#). The strategy of treatment of neuromyelitis optica spectrum disorder. *J Mult Scler.* 2015;6:1-8.
98. [Kim HJ](#), Paul F, Lana-Peixoto MA, Tenembaum S, Asgari N, Palace J, Klawiter EC, Sato DK, de Seze J, Wuerfel J, Banwell BL, Villoslada P, Saiz A, Fujihara K, Kim SH; With The Guthy-Jackson Charitable Foundation NMO International Clinical Consortium & Biorepository. MRI characteristics of neuromyelitis optica spectrum disorder: An international update. *Neurology.* 2015;84:1165-1173. [Epub 2015 Feb 18].
99. Bennett JL, de Seze J, Lana-Peixoto M, Palace J, Waldman A, Schippling S, Tenembaum S, Banwell B, Greenberg B, Levy M, Fujihara K, Chan KH, [Kim HJ](#), Asgari N, Sato DK, Saiz A, Wuerfel J, Zimmermann H, Green A, Villoslada P, Paul F; with the GJCF-ICC&BR. Neuromyelitis optica and multiple sclerosis: Seeing differences through optical coherence tomography. *Mult Scler.* 2015;21:678-688. [Epub 2015 Feb 6].
100. Kim W, Zandoná ME, Kim SH, [Kim HJ](#). Oral disease-modifying therapies for multiple sclerosis. *J Clin Neurol.* 2015;11:9-19.
101. Hyun JW, Kim SH, Jeong IH, Lee SH, [Kim HJ](#). Bright spotty lesions on the spinal cord: an additional MRI indicator of neuromyelitis optica spectrum disorder? *J Neurol Neurosurg Psychiatry.* 2015;86:1280-1282. [Epub 2015 Jan 9].
102. Kim SH, Hyun JW, Jeong IH, Joung A, Yeon JL, Dehmel T, Adams O, Kieseier BC, [Kim HJ](#). Anti-JC virus antibodies in rituximab-treated patients with neuromyelitis optica spectrum disorder. *J Neurol.* 2015;262:696-700. [Epub 2015 Jan 6].
103. Yoon JH, Yoon JY, Park HJ, Son MH, Kim SH, Kim W, [Kim HJ](#), Lee SH, Park BK. Diffuse cerebral vasospasm with infarct after intrathecal cytarabine in childhood leukemia. *Pediatr Int.* 2014;56:921-924
104. Hyun JW, Kim SH, Hyun JW, Kim W, Yeon JL, Joung AR, Sato DK, Fujihara K, [Kim HJ](#). Idiopathic aquaporin-4 antibody negative longitudinally extensive transverse myelitis. *Mult Scler.* 2015;21:710-717 [Epub 2014 Oct 10].
105. Kim SH, Huh SY, Hyun JW, Jeong IH, Lee SH, Joung AR, [Kim HJ](#). A longitudinal brain magnetic imaging study of neuromyelitis optica spectrum disorder. *PLOS ONE.* 2014;9:e108320
106. Huh SY, Kim SH, Hyun JW, Joung AR, Park MS, Kim BJ, [Kim HJ](#). Mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorder. *JAMA Neurol.* 2014;71:1372-1378. [Epub 2014 Sep 08].
107. So JS, Kim GC, Song M, Lee CG, Park E, [Kim HJ](#), Kim YS, Jun CD, Im SH. 6-Methoxyflavone Inhibits NFAT Translocation into the Nucleus and Suppresses T cell activation. *J Immunol.* 2014;193:2772-2783. [Epub 2014 Aug 11].
108. Zandoná ME, Kim SH, Hyun JW, Park B, Joo J, [Kim HJ](#). The onset location of neuromyelitis optica spectrum disorder predicts the location of subsequent relapses. *Mult Scler.* 2014;20:1908-1911. [Epub 2014 Mar 31].
109. Park HJ, Shin HY, Kang HC, Choi BO, Suh BC, [Kim HJ](#), Choi YC, Lee PH, Kim SM. Clinical and genetic aspects in twelve Korean patients with adrenomyeloneuropathy. *Yonsei Med J.* 2014;55:676-682 [Epub 2014 Apr 1].
110. Huh SY, Joo J, Kim SH, Joung AR, Park K, Kim W, Park MS, [Kim HJ](#). Validity of Korean Versions of the Multiple Sclerosis Impact Scale and the Multiple Sclerosis International Quality of Life Questionnaire. *J Clin Neurol* 2014;10:148-156
111. Kim JY, Bae JS, [Kim HJ](#), Shin HD. CD58 polymorphisms associated with the risk of neuromyelitis optica in a Korean population. *BMC Neurol.* 2014;14:57
112. Hyun JW, Kim SH, [Kim HJ](#). The systemic rheumatologic disease and neuromyelitis optica. *J Rheum Dis.* [Epub 2014 Feb 1].
113. Hyun JW, Kim SH, Hwang SH, [Kim HJ](#). Cerebral adrenomyeloneuropathy clinically mimicking primary progressive multiple sclerosis. *J Mult Scler.* 2014;5:22-24
114. [Kim HJ](#), Kim SH. Responsiveness to reduced dosage of rituximab in Chinese patients with neuromyelitis optica. *Neurology.* 2014;82:546-547.
115. Cho JY, Hong KS, [Kim HJ](#), Kim SH, Min JH, Kim NH, Ahn SW, Park MS, An JY, Kim BJ, Kim W. Disability weight for each level of the Expanded Disability Status Scale in multiple sclerosis. *Mult Scler.* 2014;7:1217-1223 [Epub 2014 Jan 7].
116. Park TJ, Kim JH, [Kim HJ](#), Bae JS, Cheong HS, Park BL, Shin HD. Lack of association between AQP4 polymorphisms and risk of inflammatory demyelinating disease in a Korean population. *Gene.* 2014;536:302-307. [Epub 2013 Dec 18].

117. Kim JY, Cheong HS, [Kim HJ](#), Kim LH, Namgoong S, Shin HD. Association analysis of IL7R polymorphisms with inflammatory demyelinating diseases. *Mol Med Rep*. 2014;9:737-743. [Epub 2013 Dec 13]
118. Hyun JW, Kim SH, Yoo H, Hong EK, Huh SY, [Kim HJ](#). Steroid-resistant relapsing IgG4-related pachymeningitis treated with methotrexate. *JAMA Neurol*. 2014;71:222-225 [Epub 2013 Dec 9].
119. Huh SY, Min JH, Kim W, Kim SH, [Kim HJ](#), Kim BJ, Kim BJ, Lee KH. The usefulness of brain MRI at onset in the differentiation of multiple sclerosis and seropositive neuromyelitis optica spectrum disorders. *Mult Scler*. 2014;20:695-704 [Epub 2013 Sep 26]
120. Shin JG, [Kim HJ](#), Park BL, Bae JS, Kim LH, Cheong HS, Shin HD. Putative association of GPC5 polymorphism with the risk of inflammatory demyelinating diseases. *J Neurol Sci*. 2013;335:82-88. [Epub 2013 Aug 30]
121. Kim JY, [Kim HJ](#), Cheong HS, Bae JS, Kim JH, Park BL, Shin HD. Lack of association between CD226 genetic variants and inflammatory demyelinating diseases in Korean population. *Neuro Endocrinol Lett*. 2013;34:402-408. [Epub 2013 Aug 3]
122. Kim SH, Huh SY, Lee SJ, Joung AR, [Kim HJ](#). A five-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder. *JAMA Neurol*. 2013;1:1110-1117 [Epub 2013 Jul 29]
123. Huh SY, Kim SH, Kim W, Lee SH, Park MS, Ahn SW, Kim BJ, Cho JY, [Kim HJ](#). Evaluation of McDonald MRI criteria for dissemination in space in Korean patients with clinically isolated syndromes. *Mult Scler*. 2014;20:492-495. [Epub 2013 Jul 25]
124. Darlington PJ, Touil T, Doucet JS, Gaucher D, Zeidan J, Gauchat D, Corsini R, [Kim HJ](#), Duddy M, Jalili F, Arbour N, Kebir H, Chen J, Arnold DL, Bowman M, Antel J, Prat A, Freedman MS, Atkins H, Sekaly R, Cheynier R, Bar-Or A; for the Canadian MS/BMT Study Group. Diminished Th17 (not Th1) responses underlie multiple sclerosis disease abrogation after hematopoietic stem cell transplantation. *Ann Neurol*. 2013;73:341-354. [Epub 2013 Mar 5]
125. Kim SH, Huh SY, Kim W, Park MS, Ahn SW, Cho JY, Kim BJ, [Kim HJ](#). Clinical characteristics and outcome of multiple sclerosis in Korea: Does multiple sclerosis in Korea really differ from that in the Caucasian populations? *Mult Scler*. 2013;19:1493-1498 [Epub 2013 Feb 13]
126. Kim W, Kim SH, Huh SY, Kong SY, Choi YJ, Cheong HJ, [Kim HJ](#). Reduced antibody formation after influenza vaccination in patients with neuromyelitis optica spectrum disorder treated with rituximab. *Eur J Neurol*. 2013;20:975-980. [Epub 2013 Mar 22]
127. Carroll WM, Saïda , [Kim HJ](#), Kira J, Kermodé AG, Tsai CP, Fujihara K, Kusunoki S, Tanaka M, Kim KK, Bates D. A guide to facilitate the early treatment of patients with idiopathic demyelinating disease (multiple sclerosis and neuromyelitis optica). *Mult Scler*. 2013;19:1371-1380. [Epub 2013 Jan 16]
128. Kim SH, Kim W, Huh SY, Lee KY, Jung IJ, [Kim HJ](#). Clinical efficacy of plasmapheresis in patients with neuromyelitis optica spectrum disorder and effects on circulating anit-aquaporin-4 antibody levels. *J Clin Neuro* 2013;9:36-42 [Epub 2013 Jan 3]
129. Kim W, Kim SH, Huh SY, [Kim HJ](#). Brain abnormalities in neuromyelitis optica spectrum disorder. *Mult Scler Int*. 2012;20:735486 [Epub 2012 Dec 3]
130. Chung SE, Cheong HK, Park JH, [Kim HJ](#). Burden of multiple sclerosis in Korea. *Epidemiol Health* 2012;34:e2012008 [Epub 2012 Nov 30]
131. Park TJ, [Kim HJ](#), Kim JH, Bae JS, Cheong HS, Park BL, Shin HD. Associations of CD6, TNFRSF1A, and IRF8 polymorphisms with risk of inflammatory demyelinating diseases. *Neuropathol Appl Neurobiol*. 2013;39:519-30. [Epub 2012 Sep 21]
132. Kim SH, Kim W, Kook MC, Hong EK, [Kim HJ](#). Central nervous system aquaporin-4 autoimmunity presenting with an isolated cerebral abnormality. *Mult Scler*. 2012;18:1340-1343. [Epub 2012 Jul 3]
133. Kim SH, [Kim HJ](#). Lack of response to rituximab therapy in patients with neuromyelitis optica: True non-responders or insufficient treatment? *J Neurol Sci*. 2012;319:171. [Epub 2012 May 26]
134. Kim SH, Kim W, Li XF, Jung IJ, [Kim HJ](#). Clinical spectrum of CNS aquaporin-4 autoimmunity. *Neurology*. 2012;78:1179-1185
135. Kim W, Kim SH, Nakashima I, Takai Y, Fujihara K, Leite MI, Kitley J, Palace J, Santos E, Coutinho E, da Silva AM, Kim BJ, Kim BJ, Ahn SW, [Kim HJ](#). Influence of pregnancy on neuromyelitis optica spectrum disorder. *Neurology*. 2012;78:1264-1267
136. Kim SH, Kim W, Li XF, Jung IJ, [Kim HJ](#). Does interferon beta exacerbate neuromyelitis optica spectrum disorders? *Mult Scler*. 2012;18:1480-1483. [Epub 2012 Feb 21]
137. Lee KY, Kim YJ, Yoo H, Lee SH, Park JB, [Kim HJ](#). Human brain endothelial cell-derived COX-2 facilitates extravasation of breast cancer cells across the blood-brain barrier. *Anticancer Res*. 2011;31:4307-4314
138. Kim W, Lee JE, Li XF, Kim SH, Han BG, Lee BI, Kim JK, Choi K, [Kim HJ](#). Quantitative measurement of anti-aquaporin-4 antibodies by enzyme-linked immunosorbent assay using purified recombinant human aquaporin-4. *Mult Scler* 2012;18:578-586. [Epub 2011 Sep 30]
139. Kim W, Kim SH, [Kim HJ](#). New Insights into Neuromyelitis Optica. *J Clin Neuro* 2011;7:115-127.
140. Kim SH, Kim W, [Kim HJ](#). Current treatment approaches for neuromyelitis optica. *Journal of Multiple Sclerosis*. 2011;2:45-51
141. Kim SH, Kim W, Li XF, Jung IJ, [Kim HJ](#). Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years. *Arch Neurol*. 2011;68:1412-1420 [Epub 2011 July 11]
142. Nakashima I, Takahashi T, Cree BA, [Kim HJ](#), Suzuki C, Genain CP, Vincent T, Fujihara K, Itoyama Y, Bar-Or A. Transient increases in anti-aquaporin-4 antibody titers following rituximab treatment in neuromyelitis optica, in association with elevated serum BAFF levels. *J Clin Neurosci*. 2011;18:997-998. [Epub 2011 May 11]
143. Kim W, Kim SH, Lee SH, Li XF, [Kim HJ](#). Brain abnormalities as an initial manifestation of neuromyelitis optica spectrum disorder. *Mult Scler*. 2011;17:1107-1112 [Epub 2011 May 4]
144. Kim SH, Kim W, Lee KW, Hong EK, [Kim HJ](#). Tumefactive demyelination, an uncommon form of tacrolimus neurotoxicity. *Neurology*. 2011;76:672-674
145. Kim SH, Kim W, Li XF, Park MS, Sohn EH, [Kim HJ](#). Efficacy and Safety of Mitoxantrone in Patients with Highly Relapsing Neuromyelitis Optica. *Arch Neurol*. 2011;68:473-479. [Epub 2010 Dec 13]
146. Kim NH, [Kim HJ](#), Cheong HK, Kim BJ, Lee KH, Kim EH, Kim EA, Kim S, Park MS, Yoon WT. The prevalence of multiple sclerosis. *Neurology*. 2010;75:1432-1438.
147. Lim BC, Hwang H, Kim KJ, Hwang YS, Cheon JE, Kim IO, [Kim HJ](#), Chae JH. Relapsing demyelinating CNS disease in a Korean pediatric population: Multiple sclerosis versus neuromyelitis optica. *Mult Scler*. 2011;17:67-73 [Epub 2010 Sep 21]
148. Kim YJ, Cho KH, Kim JY, Lim YK, Min HS, Lee SH, [Kim HJ](#), Gwak HS, Yoo H, Lee SH. Single dose versus fractionated stereotactic radiotherapy for brain metastasis. *Int J Radiat Oncol*. 2011;81:483-489 [Epub 2010 Aug 26]
149. Kim W, Park MS, Lee SH, Kim SH, Jung IJ, Takahashi T, Misu T, Fujihara K, [Kim HJ](#). Characteristic brain MRI abnormality in CNS aquaporin-4 autoimmunity. *Multiple sclerosis*. 2010;16:1229-1236. [Epub 2010 Aug 4]
150. Martiello M, [Kim HJ](#), Kim W, Brum DG, Barreira A, Kingsbury D, Plant G, Adoni T, Lennon V, Weinschenker B. Familial neuromyelitis optica. *Neurology*. 2010;75 310-315
151. Choi IG, Woo SI, [Kim HJ](#), Kim DJ, Park BL, Cheong HS, Pasaje CFA, Park TJ, Bae JS, Shin HD. Lack of association between PRNP M129V polymorphism and multiple sclerosis, mild cognitive impairment, alcoholism and schizophrenia in a Korean population. *Dis Markers*. 2010;28:315-321
152. Kim SK, Im HJ, Kim W, Kim TS, Hwangbo B, [Kim HJ](#). F-18 fluorodeoxyglucose and F-18 fluorothymidine positron emission tomography/computed tomography imaging in a case of neurosarcoidosis. *Clin Nucl Med*. 2010;35:67-70.
153. [Kim HJ](#), Park HY, Kim E, Lee KS, Kim KK, Choi BO, Kim SM, Bae JS, Lee SO, Chun JY, Park TJ, Cheong HS, Jo I, Shin HD. Common CYP7A1 promoter polymorphism associated with risk of neuromyelitis optica. *Neurobiol Dis*. 2010;37:349-355. [Epub 2009 Oct 20]
154. Kim W, [Kim HJ](#). Multiple sclerosis. *J Korean Med Assoc*. 2009;52:665-676.
155. Min JH, [Kim HJ](#), Kim BJ, Lee KW, Sunwoo IN, Kim SM, Kim BJ, Kim SH, Park MS, Waters P, Vincent A, Sung JJ, Lee KH. Brain abnormalities in Sjogren syndrome with recurrent CNS manifestations: association with neuromyelitis optica. *Multiple sclerosis*. 2009;15:1069-1076.
156. [Kim HJ](#), Kim W. Emerging new therapies in multiple sclerosis. *J Korean Neurol Ass*. 2008;26:S260-267.
157. [Kim HJ](#), Park MS. Recent update of multiple sclerosis and neuromyelitis optica. *J Korean Neurol Ass*. 2007;25:S182-188.
158. Duddy M, Niino M, Adatia F, Hebert S, Freedman M, Atkins H, [Kim HJ](#), Bar-Or A. Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis. *J Immunol*. 2007;178:6092-6099.
159. [Kim HJ](#). Pathogenesis of multiple sclerosis. *J Korean Neurol Ass*. 2006;24:S57-63.

160. Niino M, Bodner C, Simard M, Alatab S, Gano D, [Kim HJ](#), Trigueiro M, Racicot D, Guerette C, Antel J, Fournier A, GrandMaison F, Bar-Or A. Natalizumab effect on immune cell responses in multiple sclerosis. *Ann Neurol*. 2006;59:748-754.
161. Cho JY, [Kim HJ](#). Immunopathogenetic mechanism based treatment of multiple sclerosis. *Hanyang Medical Review*. 2006;1:69-76
162. [Kim HJ](#), Ifergan I, Antel JP, Séguin R, Duddy M, Lapierre Y, Jalili F, Bar-Or A. Type 2 monocyte and microglia differentiation mediated by glatiramer acetate therapy in patients with multiple sclerosis. *J Immunol*. 2004;172:7144-53.
163. [Kim HJ](#), Biernacki K, Prat A, Antel JP, Bar-Or A. Inflammatory potential and migratory capacities across human brain endothelial cells of distinct glatiramer acetate-reactive T cells generated in treated multiple sclerosis patients. *Clin Immunol*. 2004;111:38-46.
164. Bar-Or A, Nuttall RK, Duddy M, Alter A, [Kim HJ](#), Ifergan I, Pennington CJ, Bourgoin P, Edwards DR, Yong VW. Analyses of all matrix metalloproteinase members in leukocytes emphasize monocytes as major inflammatory mediators in multiple sclerosis. *Brain*. 2003;126:2738-49
165. [Kim HJ](#), Kim SY, Lee KB, Lee KW, Oh MD, Choe KW. Neurologic Complications of Human Immunodeficiency Virus-type 1 Infection in Korea. *J Korean Med Sci*. 2003;18:149-157
166. Séguin R, Biernacki K, Prat A, Wosik K, [Kim HJ](#), Blain M, McCreia E, Bar-Or A, Antel JP. Differential Effects of Th1 and Th2 Lymphocyte Supernatants Upon Human Microglia. *Glia*. 2003;42:36-45
167. [Kim HJ](#), Antel JP, Duquette P, Alleva DG, Conlon PJ, Bar-Or A. Persistence of immune responses to altered and native myelin antigens in patients with multiple sclerosis treated with altered peptide ligand. *Clin Immunol*. 2002;104:105-14
168. [Kim HJ](#), Jeon BS, Lee KW. Hemimasticatory Spasm Associated with Localized Scleroderma and Facial Hemiatropy. *Arch Neurol* 2000;57:576-580
169. Kim DE, [Kim HJ](#), Kim YA, Lee KW. Kaposi's sarcoma herpesvirus-associated Castleman's disease with POEMS syndrome. *Muscle & Nerve* 2000;23:436-9
170. Lee KB, Choe GY, [Kim HJ](#), Kim HW, Chi JG, Choe KW, Lee KW. AIDS Dementia Complex : Report of an Autopsy Case. *J Korean Neurol Ass* 2000;18:472-75
171. Park EM, Yoon BW, Jang JH, [Kim HJ](#), Roh JK. Adult-onset Moyamoya Disease : Clinical Features and Prognosis *J Korean Neurol Ass* 2000;18:1~7
172. Lee KW, Lee SH, [Kim HJ](#), Kim JM, Choi YM, Motomura M. Experimental Autoimmune Myasthenia Gravis and CD5+ B-lymphocyte Expression. *J Korean Med Sci* 1999;14:623-628
173. Kang DW, Jeong IK, [Kim HJ](#), Lee KW. Neurologic Manifestations of Churg-Strauss syndrome. *J Korean Neurol Ass* 1999;17:836~840
174. Cho JY, Choi WJ, Kim SH, Sung JJ, [Kim HJ](#), Park KS, Choi KY, Lee KW. Histopathologic Features and CD5+ B-lymphocyte Expression in the Experimental Allergic Neuritis. *Ann Clin Neurophysiology*. 1999;1:91-98
175. [Kim HJ](#). Clinical Characteristics of Thymic Tumor-associated Myasthenia Gravis. A thesis for the degree of master in medicine. Archives of Seoul National University Library 1999
176. Park JM, [Kim HJ](#), Yun CH, Lee YS, Roh JK, Lee KW. The Late Blink Reflex Response in Patients with Thalamic Hemorrhage. *J Kor Neurol Ass* 1999;17:661~667
177. [Kim HJ](#), Chang KH, Kim SH, Kim KK, Lee KW. Differentiation of idiopathic acute transverse myelitis from myelopathic multiple sclerosis by MRI. *J Korean Neurol Ass* 1999;17(5):651~660
178. [Kim HJ](#), Jeon BS. Acetazoamide-responsive Hereditary Paroxysmal Ataxia. *J Korean Med Sci* 1998;13:196-200
179. [Kim HJ](#), Choi SH, Oh JE, Lee KW. Two Cases of Polymyositis Presenting with Respiratory Failure. *J Korean Neurol Ass* 1997;15(4):926-930
180. Kim JS, [Kim HJ](#), Lee KH, Roh JK. Two Cases of WEBINO Syndrome. *J Korean Neurol Ass* 1996;14(2):612-619